Cell therapy for active uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a new cell therapy (TRX103) to see if it can safely reduce inflammation in people with active uveitis that is not caused by infection. The treatment aims to calm the immune system to control the disease and may help avoid long-term steroid use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You need to have active uveitis that affects the middle or back of the eye, not just the front.
- You cannot be on certain immune-suppressing medications at the time of the study, or you must have stopped them for a specific period.
- You must not have other serious eye conditions that could interfere with the study.
- You must have normal heart and kidney function, and no active infections or recent surgeries.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This study follows people with non-infectious uveitis (inflammation inside the eye) that affects the middle or back of the eye. It aims to understand the disease better and see how different treatments work, which may help improve future care.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Hear when a new Non Infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.